{"id":"https://openalex.org/W2985221104","doi":"https://doi.org/10.1182/blood-2019-125650","title":"A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","display_name":"A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2985221104","doi":"https://doi.org/10.1182/blood-2019-125650","mag":"2985221104"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-125650","doi":"https://doi.org/10.1182/blood-2019-125650","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-125650","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062534813","display_name":"Tycel Jovelle Phillips","orcid":"https://orcid.org/0000-0003-2143-9672","observed_orcids":["https://orcid.org/0000-0003-2143-9672"]},"institutions":[{"id":"https://openalex.org/I4390039285","display_name":"U-M Rogel Cancer Center","ror":"https://ror.org/05asdy483","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210114445","https://openalex.org/I4390039285"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tycel J. Phillips","raw_affiliation_strings":["University of Michigan Rogel Cancer Center, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan Rogel Cancer Center, Ann Arbor, MI","institution_ids":["https://openalex.org/I4390039285"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086354986","display_name":"Gilles A. Salles","orcid":"https://orcid.org/0000-0002-9541-8666","observed_orcids":["https://orcid.org/0000-0002-9541-8666"]},"institutions":[{"id":"https://openalex.org/I4210113288","display_name":"H\u00f4pital Lyon Sud","ror":"https://ror.org/023xgd207","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210100596","https://openalex.org/I4210113288"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Gilles Salles","raw_affiliation_strings":["Lyon-Sud Hospital, University of Lyon, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lyon-Sud Hospital, University of Lyon, Lyon, France","institution_ids":["https://openalex.org/I4210113288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042844727","display_name":"Daniel Jeffrey Landsburg","orcid":"https://orcid.org/0000-0002-5077-4181","observed_orcids":["https://orcid.org/0000-0002-5077-4181"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel J. Landsburg","raw_affiliation_strings":["Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010723896","display_name":"Giuseppe Gritti","orcid":"https://orcid.org/0000-0002-6789-5123","observed_orcids":["https://orcid.org/0000-0002-6789-5123"]},"institutions":[{"id":"https://openalex.org/I4210106645","display_name":"Ospedale Papa Giovanni XXIII","ror":"https://ror.org/01savtv33","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210106645"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giuseppe Gritti","raw_affiliation_strings":["Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy","institution_ids":["https://openalex.org/I4210106645"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036220283","display_name":"Krish Patel","orcid":"https://orcid.org/0000-0002-2446-098X","observed_orcids":["https://orcid.org/0000-0002-2446-098X","https://orcid.org/0009-0009-0218-0651"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Krish Patel","raw_affiliation_strings":["Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003078312","display_name":"Herv\u00e9 Tilly","orcid":"https://orcid.org/0000-0001-7022-5246","observed_orcids":["https://orcid.org/0000-0001-7022-5246"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4387152093","display_name":"Centre Henri Becquerel","ror":"https://ror.org/00whhby07","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210141925","https://openalex.org/I4387152093"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Herve Tilly","raw_affiliation_strings":["Department of Haematology and INSERM 1245, Henri Becquerel Center, Rouen, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Haematology and INSERM 1245, Henri Becquerel Center, Rouen, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4387152093"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033073385","display_name":"Catherine Thi\u00e9blemont","orcid":"https://orcid.org/0000-0002-9941-2448","observed_orcids":["https://orcid.org/0000-0002-9941-2448","https://orcid.org/0000-0002-7109-6949"]},"institutions":[{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Catherine Thieblemont","raw_affiliation_strings":["Saint Louis University Hospital, Division of Hemato-Oncology, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saint Louis University Hospital, Division of Hemato-Oncology, Paris, France","institution_ids":["https://openalex.org/I4210144610"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071138712","display_name":"William M. Townsend","orcid":"https://orcid.org/0000-0003-3975-2448","observed_orcids":["https://orcid.org/0000-0003-3975-2448","https://orcid.org/0000-0002-2991-2594"]},"institutions":[{"id":"https://openalex.org/I1289784979","display_name":"University College Hospital","ror":"https://ror.org/00wrevg56","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289784979","https://openalex.org/I1340918713"]},{"id":"https://openalex.org/I1340918713","display_name":"University College London Hospitals NHS Foundation Trust","ror":"https://ror.org/042fqyp44","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1340918713"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"William Townsend","raw_affiliation_strings":["Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1289784979","https://openalex.org/I1340918713"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011436623","display_name":"Silvia Ferrari","orcid":"https://orcid.org/0000-0002-9917-2843","observed_orcids":["https://orcid.org/0000-0002-9917-2843"]},"institutions":[{"id":"https://openalex.org/I4210106645","display_name":"Ospedale Papa Giovanni XXIII","ror":"https://ror.org/01savtv33","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210106645"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Silvia Ferrari","raw_affiliation_strings":["Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy","institution_ids":["https://openalex.org/I4210106645"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056072555","display_name":"Kate F. Stumpo","orcid":"https://orcid.org/0000-0001-7849-7676","observed_orcids":["https://orcid.org/0000-0001-7849-7676"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kate F. Stumpo","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081187321","display_name":"Shilpi Katyayan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I95746587","display_name":"Cytel (United States)","ror":"https://ror.org/01ftkxq60","country_code":"US","type":"company","lineage":["https://openalex.org/I95746587"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shilpi Katyayan","raw_affiliation_strings":["Cytel Inc., Cambridge, MA","Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cytel Inc., Cambridge, MA","institution_ids":["https://openalex.org/I95746587"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039066645","display_name":"Cheryl Li","orcid":"https://orcid.org/0009-0009-5615-8046","observed_orcids":["https://orcid.org/0009-0009-5615-8046"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cheryl Li","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110958675","display_name":"Harry H. Miao","orcid":"https://orcid.org/0009-0003-7480-7405","observed_orcids":["https://orcid.org/0009-0003-7480-7405"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harry Miao","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071476899","display_name":"Igor Proscurshim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Igor Proscurshim","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004025497","display_name":"Ajay K. Gopal","orcid":"https://orcid.org/0000-0003-3023-6834","observed_orcids":["https://orcid.org/0000-0003-3023-6834"]},"institutions":[{"id":"https://openalex.org/I1332479046","display_name":"Seattle Cancer Care Alliance","ror":"https://ror.org/03jq88n71","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1332479046"]},{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajay K. Gopal","raw_affiliation_strings":["Division of Medical Oncology, Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology, Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance, Seattle, WA","institution_ids":["https://openalex.org/I1332479046","https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":15,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"5310","last_page":"5310"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9380000233650208},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.9860000014305115},{"id":"https://openalex.org/keywords/syk","display_name":"Syk","score":0.8939999938011169},{"id":"https://openalex.org/keywords/fms-like-tyrosine-kinase-3","display_name":"FMS-like tyrosine kinase 3","score":0.9879999756813049},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.7049999833106995},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6240000128746033},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8209999799728394},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.890999972820282},{"id":"https://openalex.org/keywords/oral-kinase-inhibitor","display_name":"oral kinase inhibitor","score":0.5379999876022339}],"concepts":[{"id":"https://openalex.org/C35174551","wikidata":"https://www.wikidata.org/wiki/Q7660502","display_name":"Syk","level":4,"score":0.7850075960159302},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.690313458442688},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.6034353375434875},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5414640307426453},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.47371214628219604},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4667535126209259},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.4353216886520386},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4317231774330139},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30001747608184814},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2909491956233978},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2322341501712799},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.18744391202926636},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.13438457250595093},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-125650","doi":"https://doi.org/10.1182/blood-2019-125650","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-125650","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2784637065","https://openalex.org/W2622365580","https://openalex.org/W3019564266","https://openalex.org/W2568855134","https://openalex.org/W2624931958","https://openalex.org/W2906781254","https://openalex.org/W2978344467","https://openalex.org/W3212184481","https://openalex.org/W4310679729","https://openalex.org/W2765354892"],"abstract_inverted_index":{"Background":[0],"TAK-659":[1,22,68,170,177,224,229,312,318,404,688,718,1181],"is":[2,1182],"an":[3,55,87,642,747,758,782,801,819,834,857,873,903,916,929,999,1024,1183],"investigational,":[4,1184],"oral,":[5,1185],"reversible,":[6,1186],"and":[7,16,36,65,221,225,309,333,356,420,454,461,464,481,500,522,544,547,616,631,692,705,733,1142,1162,1175,1187,1196],"potent":[8,1188],"dual":[9,1189],"inhibitor":[10,1190],"of":[11,30,67,82,97,138,213,223,325,360,379,414,431,476,483,495,539,553,565,572,594,644,649,672,681,717,750,761,785,804,822,837,860,876,906,919,932,1002,1027,1044,1067,1085,1102,1119,1191],"spleen":[12,1192],"tyrosine":[13,18,1193,1198],"kinase":[14,19,1194,1199],"(SYK)":[15,1195],"FMS-like":[17,1197],"3":[20,372,1200],"(FLT3).":[21],"has":[23],"demonstrated":[24],"inhibitory":[25],"activity":[26,39],"in":[27,40,48,73,166,178,197,408,425,458,467,478,485,493,497,502,563,577,590,610,613,618,628,638,663,667,683,700,719],"preclinical":[28],"models":[29],"diffuse":[31],"large":[32,347],"B-cell":[33,348],"lymphoma":[34,349,354,540],"(DLBCL)":[35],"single-agent":[37],"clinical":[38],"patients":[41,74,108,168,305,326,361,385,438,477,484,496,554,612,622,657,701],"with":[42,75,702],"relapsed":[43,144],"or":[44,121,146,176,206,317,374,397,604,752,763,787,806,824,839,862,878,908,921,934,1004,1029],"refractory":[45],"(R/R)":[46],"DLBCL":[47,77,341],"a":[49,70,160,179,289,412,429,587,624,634,1040,1063,1081,1098,1115],"phase":[50,58,156,163],"1":[51,215,249,432,666],"study.":[52],"We":[53],"conducted":[54],"open-label,":[56],"multicenter,":[57],"2":[59,157,236,370,671],"study":[60,104,158,258,603,660,674,726],"to":[61,186,189,217,226,232,234,254,264,393,557,575,586,599,679,730],"evaluate":[62],"the":[63,101,103,219,257,278,444,508,529,570,600,714,725],"efficacy":[64,682,716],"safety":[66,220,710],"as":[69],"single":[71],"agent":[72],"R/R":[76,127,703],"after":[78,129,145],"\u22652":[79,130],"prior":[80,136,377],"lines":[81,137,378],"chemotherapy":[83],"(NCT03123393),":[84],"which":[85,92,167,559,595],"represents":[86],"unmet":[88],"medical":[89],"need":[90],"for":[91,150,208,294],"there":[93,706],"was":[94,275,284,327,580,651,675,735],"no":[95,132,708],"standard":[96],"care":[98],"available":[99],"at":[100],"time":[102],"opened.":[105],"Methods":[106],"Eligible":[107],"were":[109,216,252,336,340,362,448,472,491,515,537,560,596,696,707],"aged":[110],"\u226518":[111],"years,":[112],"had":[113,306,310,368,387],"histologically":[114],"confirmed":[115],"DLBCL,":[116,704],"including":[117],"de":[118],"novo":[119],"disease":[120,123,128,202,395,601],"transformed":[122],"from":[124,183,271],"indolent":[125],"NHL,":[126],"but":[131],"more":[133],"than":[134],"4":[135,375,662],"chemotherapy.":[139],"Patients":[140,367,402],"must":[141],"have":[142],"either":[143],"not":[147,342,676,728],"been":[148,307],"eligible":[149],"autologous":[151],"stem":[152],"cell":[153],"transplant.":[154],"This":[155,267],"included":[159],"lead-in":[161],"dose-exploration":[162],"(Stage":[164],"1)":[165],"received":[169,311,369,411,428],"100":[171,190,313,405,689],"mg":[172,185,188,191,314,406,690],"QD":[173,192,315,407,691],"(Cohort":[174,195],"A)":[175],"3-dose-level":[180],"ramp-up":[181,319,423,693],"schema":[182],"60":[184],"80":[187],"per":[193,243],"cycle":[194,434],"B)":[196],"28-day":[198],"treatment":[199,416,433],"cycles":[200,417],"until":[201],"progression,":[203],"unacceptable":[204],"toxicity,":[205],"withdrawal":[207],"other":[209,357],"reasons.":[210],"The":[211,322,567,687],"objectives":[212],"Stage":[214,235,248,265,272,670,684,731],"assess":[218],"tolerability":[222],"select":[227],"one":[228],"dose":[230,250],"regimen":[231],"proceed":[233,729],"based":[237],"on":[238,659,713,746,757,781,800,818,833,856,872,902,915,928,998,1023],"overall":[239],"response":[240,626,636,650],"rate":[241,571],"(ORR)":[242],"investigator":[244],"assessment.":[245],"If":[246],"both":[247],"regimens":[251],"determined":[253],"be":[255,260],"ineffective,":[256],"would":[259],"terminated":[261],"without":[262],"proceeding":[263],"2.":[266],"abstract":[268],"presents":[269],"data":[270,299,382],"1.":[273,685],"Safety":[274],"assessed":[276,285],"using":[277,288],"NCI":[279],"CTCAE,":[280],"version":[281],"4.03.":[282],"Efficacy":[283],"by":[286,474],"investigators":[287],"modified":[290],"2007":[291],"IWG":[292],"criteria":[293],"malignant":[295],"lymphoma.":[296],"Results":[297],"At":[298,381],"cutoff":[300],"(April":[301],"25,":[302],"2019),":[303],"49":[304],"enrolled":[308],"(n=24)":[316],"dosing":[320,424,694],"(n=25).":[321],"median":[323,413,430],"age":[324],"65":[328],"years":[329],"(range,":[330],"30-81":[331],"years)":[332],"29":[334],"(59%)":[335],"male.":[337],"Disease":[338],"subtypes":[339],"otherwise":[343],"specified":[344],"(n=45),":[345],"T-cell/histiocyte-rich":[346],"(n=1),":[350],"grade":[351,511,533],"3b":[352],"follicular":[353],"(n=2),":[355],"(n=1).":[358],"61%":[359],"Ann":[363],"Arbor":[364],"stage":[365],"IV.":[366],"(49%),":[371],"(45%),":[373],"(6%)":[376],"therapy.":[380],"cutoff,":[383],"44":[384],"(90%)":[386],"discontinued":[388,555],"treatment,":[389],"most":[390,445,509,530],"frequently":[391,531],"due":[392,556,574,585,678],"progressive":[394],"(61%)":[396],"adverse":[398],"events":[399],"(AEs;":[400],"14%).":[401],"administered":[403,422],"Cohort":[409,426,459,468,479,486,498,503,506,527,614,619,664,668],"A":[410,480,499,615],"1.5":[415],"(range":[418,435,653],"1-14),":[419],"those":[421],"B":[427],"1-9).":[436],"All":[437],"experienced":[439,473],"\u22651":[440],"treatment-emergent":[441],"AE":[442],"(TEAE);":[443],"frequent":[446],"(\u226530%)":[447],"pyrexia":[449,462],"(42%),":[450],"increased":[451,518,545],"aspartate":[452],"aminotransferase,":[453],"cough":[455],"(both":[456,524],"38%)":[457],"A,":[460,507,665],"(44%)":[463],"fatigue":[465],"(32%)":[466],"B.":[469,487,504,620,669],"Treatment-related":[470],"TEAEs":[471,490,513,535,576],"88%":[475],"60%":[482],"Grade":[488],"\u22653":[489,512,534],"reported":[492,532],"92%":[494],"72%":[501],"In":[505,526],"common":[510],"(\u226515%)":[514],"anemia":[516],"(21%),":[517],"blood":[519],"creatinine":[520],"phosphokinase,":[521],"hypophosphatemia":[523],"17%).":[525],"B,":[528],"(\u22655%)":[536],"progression":[538],"(12%),":[541],"anemia,":[542],"neutropenia,":[543],"amylase":[546],"lipase":[548],"(all":[549],"8%).":[550],"Overall,":[551],"33%":[552],"TEAEs,":[558],"considered":[561],"treatment-related":[562],"18%":[564],"patients.":[566],"difference":[568],"between":[569],"discontinuation":[573],"each":[578,591,629,639],"cohort":[579],"negligible.":[581],"Three":[582],"on-study":[583],"deaths":[584],"TEAE":[588],"occurred":[589,609],"cohort,":[592],"all":[593],"deemed":[597],"related":[598],"under":[602],"complications":[605],"thereof.":[606],"Dose":[607],"reductions":[608],"5":[611],"none":[617],"Two":[621],"achieved":[623,633],"complete":[625],"(1":[627],"cohort)":[630],"6":[632],"partial":[635],"(3":[637],"cohort),":[640],"giving":[641],"ORR":[643],"16%":[645],"(Table).":[646],"Median":[647],"duration":[648],"8.3":[652],"0-13)":[654],"months.":[655],"Five":[656],"remain":[658],"drug;":[661],"this":[673,720],"initiated":[677],"lack":[680],"Conclusions":[686],"schedules":[695],"generally":[697],"well":[698],"tolerated":[699],"new":[709],"signals.":[711],"Based":[712],"limited":[715],"heavily":[721],"pretreated":[722],"patient":[723],"population,":[724],"did":[727],"2,":[732],"enrollment":[734],"closed.":[736],"Disclosures":[737],"Phillips:":[738],"Seattle":[739,883,887,1145,1170],"Genetics:":[740,884,888],"Consultancy;":[741,743,767,971,977,983,985,1164],"Gilead:":[742,990,1011],"Incyte:":[744,1143],"Membership":[745,756,780,799,817,832,855,871,901,914,927,997,1022],"entity's":[748,759,783,802,820,835,858,874,904,917,930,1000,1025],"Board":[749,760,784,803,821,836,859,875,905,918,931,1001,1026],"Directors":[751,762,786,805,823,838,861,877,907,920,933,1003,1028],"advisory":[753,764,788,807,825,840,863,879,909,922,935,1005,1030],"committees;":[754,765,808,841,910,936],"Celgene:":[755,852,900,926,960,978,1019],"Bayer:":[766],"Abbvie:":[768,947],"Research":[769,773,881,892,895,898,924,938,966,980,1009,1177],"Funding;":[770,774,882,893,896,899,925,981,1010],"Pharmacyclics:":[771],"Consultancy,":[772,778,794,797,815,831,853,870,913,957,961,965,973,979,1033],"Genentech:":[775],"Consultancy.":[776],"Salles:Takeda:":[777],"Honoraria,":[779,798,816,843,854,1008],"committees,":[789,826,864,880,923],"Other:":[790,827,844,865,944,948,953],"Educational":[791,828,845,866],"events;":[792,829,846],"Epizyme:":[793],"Honoraria;":[795,848,942,987,989,991,993,995,1012,1014,1016,1018,1020,1144],"Merck:":[796],"Novartis,":[809],"Servier,":[810],"AbbVie,":[811],"Karyopharm,":[812],"Kite,":[813],"MorphoSys:":[814],"Autolus:":[830],"Amgen:":[842],"BMS:":[847,986],"Roche,":[849],"Janssen,":[850,1128,1148,1173],"Gilead,":[851,1129,1149],"events.":[867],"Landsburg:Curis,":[868],"INC:":[869,912],"Speakers":[885,889,958,962,968,974],"Bureau;":[886,890,959,963,969],"Takeda:":[891,894],"Triphase:":[897,937],"Curis,":[911],"Funding.":[939,1178],"Gritti:Autolus":[940],"Ltd:":[941],"Roche:":[943],"Not":[945,949,954],"stated;":[946,950],"Becton":[951],"Dickinson:":[952],"stated.":[955],"Patel:Genentech:":[956],"AstraZeneca:":[964],"Funding,":[967],"Sunesis:":[970],"Pharmacyclics/Janssen:":[972],"Bureau.":[975],"Tilly:Roche:":[976],"Astra-Zeneca:":[982],"Karyopharm:":[984],"Janssen:":[988,1017],"merck:":[992],"servier:":[994],"roche:":[996],"committees.":[1006,1031],"Thieblemont:Roche:":[1007],"Novartis:":[1013],"Kyte:":[1015],"Cellectis:":[1021],"Townsend:Roche:":[1032],"Honoraria.":[1034],"Stumpo:Millennium":[1035],"Pharmaceuticals,":[1036,1059,1077,1094,1111],"Inc.,":[1037,1060,1078,1095,1112],"Cambridge,":[1038,1061,1079,1096,1113],"MA,":[1039,1062,1080,1097,1114],"wholly":[1041,1064,1082,1099,1116],"owned":[1042,1065,1083,1100,1117],"subsidiary":[1043,1066,1084,1101,1118],"Takeda":[1045,1068,1086,1103,1120],"Pharmaceutical":[1046,1069,1087,1104,1121],"Company":[1047,1070,1088,1105,1122],"Limited:":[1048,1071,1089,1106,1123],"Employment;":[1049,1072,1090],"Astra":[1050],"Zeneca:":[1051],"Equity":[1052,1056,1108],"Ownership;":[1053],"Teva":[1054],"Pharmaceuticals:":[1055],"Ownership.":[1057,1109],"Katyayan:Millennium":[1058],"Cytel":[1073],"Inc.:":[1074],"Employment.":[1075,1092,1124],"Li:Millennium":[1076],"Pfizer:":[1091],"Miao:Millennium":[1093],"Employment,":[1107],"Proscurshim:Millennium":[1110],"Gopal:Seattle":[1125],"Genetics,":[1126,1146,1171],"Pfizer,":[1127,1147,1172],"Sanofi,":[1130,1150],"Spectrum,":[1131,1151],"Amgen,":[1132,1152],"Aptevo,":[1133,1153],"BRIM":[1134,1154],"bio,":[1135,1155],"Acerta,":[1136,1156],"I-Mab-pharma,":[1137,1157],"Takeda,":[1138,1158,1169,1174],"Compliment,":[1139,1159],"Asana":[1140,1160],"Bio,":[1141,1161],"Incyte.:":[1163],"Teva,":[1165],"Bristol-Myers":[1166],"Squibb,":[1167],"Merck,":[1168],"Effector:":[1176],"OffLabel":[1179],"Disclosure:":[1180],"(FLT3)":[1201]},"counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2019-11-22T00:00:00"}